ATE44238T1 - Vakzine fuer gramnegative bakterien und verfahren zur herstellung derselben. - Google Patents

Vakzine fuer gramnegative bakterien und verfahren zur herstellung derselben.

Info

Publication number
ATE44238T1
ATE44238T1 AT84102119T AT84102119T ATE44238T1 AT E44238 T1 ATE44238 T1 AT E44238T1 AT 84102119 T AT84102119 T AT 84102119T AT 84102119 T AT84102119 T AT 84102119T AT E44238 T1 ATE44238 T1 AT E44238T1
Authority
AT
Austria
Prior art keywords
detoxified
gram
polysaccharide
negative bacterium
vaccine
Prior art date
Application number
AT84102119T
Other languages
German (de)
English (en)
Inventor
Grace C Tsay
Michael S Collins
Original Assignee
Miles Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Inc filed Critical Miles Inc
Application granted granted Critical
Publication of ATE44238T1 publication Critical patent/ATE44238T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/802—Antibody or antigen-binding fragment thereof that binds gram-positive bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT84102119T 1983-03-14 1984-02-29 Vakzine fuer gramnegative bakterien und verfahren zur herstellung derselben. ATE44238T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/475,415 US4663160A (en) 1983-03-14 1983-03-14 Vaccines for gram-negative bacteria
EP84102119A EP0118831B1 (en) 1983-03-14 1984-02-29 Vaccines for gram-negative bacteria and method for the preparation thereof

Publications (1)

Publication Number Publication Date
ATE44238T1 true ATE44238T1 (de) 1989-07-15

Family

ID=23887470

Family Applications (1)

Application Number Title Priority Date Filing Date
AT84102119T ATE44238T1 (de) 1983-03-14 1984-02-29 Vakzine fuer gramnegative bakterien und verfahren zur herstellung derselben.

Country Status (5)

Country Link
US (1) US4663160A (OSRAM)
EP (2) EP0118831B1 (OSRAM)
JP (1) JPS59175440A (OSRAM)
AT (1) ATE44238T1 (OSRAM)
DE (1) DE3478789D1 (OSRAM)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
EP0215131B1 (en) * 1985-03-11 1992-06-17 Teijin Limited E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DK163176C (da) * 1985-09-27 1992-06-22 Schweiz Serum & Impfinst Ugiftig konjugatvaccine mod infektioner af pseudomonas aeruginosa- og escherichia coli- bakterier, fremgangsmaade til fremstilling heraf og anvendelse af vaccinen
US4755381A (en) * 1986-03-27 1988-07-05 Swiss Serum And Vaccine Institute Berne Klebsiella capsular polysaccharide vaccine
US4789544A (en) * 1986-05-23 1988-12-06 Midcon Labs. Inc. Co-vaccination using non-O-carbohydrate side-chain gram-negative bacteria preparation
DE3727987A1 (de) * 1987-08-21 1989-03-02 Sleytr Uwe B Pharmazeutische struktur
US5043158A (en) * 1987-08-21 1991-08-27 Chembiomed, Ltd. Immunogenic compositions containing ordered carriers
US5063054A (en) * 1988-04-18 1991-11-05 Joseph Chang Microbial products used for treatment of hepatitis
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
AU678549B2 (en) * 1992-01-16 1997-06-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Detoxified LPS-cholera toxin conjugate vaccine for prevention of cholera
US5554730A (en) * 1993-03-09 1996-09-10 Middlesex Sciences, Inc. Method and kit for making a polysaccharide-protein conjugate
US5695768A (en) 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US5866132A (en) * 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
US6477464B2 (en) 2000-03-09 2002-11-05 Donnelly Corporation Complete mirror-based global-positioning system (GPS) navigation solution
US6329925B1 (en) 1999-11-24 2001-12-11 Donnelly Corporation Rearview mirror assembly with added feature modular display
US6693517B2 (en) 2000-04-21 2004-02-17 Donnelly Corporation Vehicle mirror assembly communicating wirelessly with vehicle accessories and occupants
CA2333931C (en) 1998-07-15 2013-09-03 Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
CN1263510C (zh) * 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用
US7370983B2 (en) 2000-03-02 2008-05-13 Donnelly Corporation Interior mirror assembly with display
US7167796B2 (en) 2000-03-09 2007-01-23 Donnelly Corporation Vehicle navigation system for use with a telematics system
US7255451B2 (en) 2002-09-20 2007-08-14 Donnelly Corporation Electro-optic mirror cell
AU2002251807A1 (en) 2001-01-23 2002-08-19 Donnelly Corporation Improved vehicular lighting system for a mirror assembly
US7581859B2 (en) 2005-09-14 2009-09-01 Donnelly Corp. Display device for exterior rearview mirror
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2003094961A1 (en) * 2002-05-09 2003-11-20 Massimo Porro Improved polysaccharide and glycoconjugate vaccines_____________
US7310177B2 (en) 2002-09-20 2007-12-18 Donnelly Corporation Electro-optic reflective element assembly
US8663656B2 (en) 2002-10-11 2014-03-04 Novartis Ag Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA3042073C (en) 2003-01-30 2022-09-13 Novartis Vaccines And Diagnostics S.R.L. Injectable vaccines against multiple meningococcal serogroups
SI1670506T1 (sl) 2003-10-02 2013-03-29 Novartis Ag Tekoča cepiva proti multiplim meningokoknim seroskupinam
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
WO2005044861A1 (en) * 2003-10-31 2005-05-19 Wyeth Holdings Corporation Polysaccharides of helicobacter pylori
EP1713508A2 (en) * 2004-01-29 2006-10-25 Biosynexus Incorporated Use of amino-oxy functional groups in the preparation of vaccine conjugates
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
EP2272531A3 (en) 2004-04-30 2011-04-13 Novartis Vaccines and Diagnostics S.r.l. Integration of meningococcal conjugate vaccination
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
US8246993B2 (en) * 2004-06-10 2012-08-21 Cytogel Pharma, Llc Advantageous hydrogel composition
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
US20060013886A1 (en) * 2004-06-28 2006-01-19 Daqing Wu Injectable microspheres
CA2581330A1 (en) 2004-09-21 2006-03-30 The Brigham And Women's Hospital, Inc. Methods and compositions relating to mannuronic acid specific binding peptides
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
ES2383209T3 (es) 2006-03-22 2012-06-19 Novartis Ag Regímenes para la inmunización con conjugados meningococicos
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
HRP20120557T1 (hr) 2006-09-07 2012-07-31 GlaxoSmithKline@Biologicals@s@a Kombinirano cjepivo sa smanjenim količinama antigena poliovirusa
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
UY31064A1 (es) 2007-05-02 2009-01-05 Glaxosmithkline Biolog Sa Vacuna
GB0713880D0 (en) * 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US8017898B2 (en) 2007-08-17 2011-09-13 Magna Electronics Inc. Vehicular imaging system in an automatic headlamp control system
WO2009046268A1 (en) 2007-10-04 2009-04-09 Magna Electronics Combined rgb and ir imaging sensor
DK2200642T3 (da) 2007-10-19 2012-07-16 Novartis Ag Meningococvaccinepræparater
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2009215364B2 (en) 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
WO2010049806A1 (en) 2008-10-27 2010-05-06 Novartis Ag Purification method
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
CA2747340A1 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
WO2010109323A1 (en) 2009-03-24 2010-09-30 Novartis Ag Adjuvanting meningococcal factor h binding protein
JP5668049B2 (ja) 2009-03-24 2015-02-12 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質および肺炎球菌糖結合体の組み合わせ
US8679505B2 (en) 2009-04-14 2014-03-25 Novartis Ag Compositions for immunising against Staphylococcus aureus
WO2011017101A2 (en) 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
CA2773637A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
AU2010352695B2 (en) 2009-09-30 2014-08-21 Glaxosmithkline Biologicals S.A. Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
BR122019005883A8 (pt) * 2009-10-30 2022-10-04 Novartis Ag Método para liberação de polissacarídeo capsular, processo de purificação de sacarídeos capsulares tipo 5 e tipo 8 de staphylococcus aureus e composição
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
SG10201506160VA (en) 2009-12-17 2015-09-29 Fina Biosolutions Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
CA2797892C (en) 2010-05-21 2019-10-15 Cytogel Pharma, Llc Materials and methods for treatment of inflammation
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
DE202012012768U1 (de) 2011-12-06 2014-01-21 Valneva Austria Gmbh Aluminium-Verbindungen zur Verwendung in Therapeutika und Impfstoffen
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
US10596246B2 (en) 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
WO2013132043A1 (en) 2012-03-08 2013-09-12 Novartis Ag Combination vaccines with tlr4 agonists
JP2015522692A (ja) 2012-07-16 2015-08-06 ファイザー・インク 糖およびその使用
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
EP2903650B1 (en) 2012-10-02 2018-04-04 GlaxoSmithKline Biologicals SA Nonlinear saccharide conjugates
BR112015008040A2 (pt) 2012-10-12 2017-07-04 Glaxosmithkline Biologicals Sa composição de vacina, vacina de combinação, e, processos para preparar um componente ap e para a fabricação de uma composição de vacina
CA2892688A1 (en) 2012-11-30 2014-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
EP2950819B1 (en) 2013-02-01 2018-03-28 GlaxoSmithKline Biologicals SA Intradermal delivery of immunological compositions comprising toll-like receptor agonists
HK1225739A1 (zh) * 2013-12-03 2017-09-15 Virometix Ag 针对肺炎链球菌进行保护的富含脯氨酸的肽
EA034954B1 (ru) 2014-02-28 2020-04-10 Глаксосмитклайн Байолоджикалс Са МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
WO2018042017A2 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
EP3551668A1 (en) 2016-12-06 2019-10-16 GlaxoSmithKline Biologicals S.A. Purification process for capsular polysaccharide
MX2019015524A (es) 2017-06-23 2020-09-10 Univ Maryland Composiciones inmunogenicas.
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
GB202013262D0 (en) 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH396316A (de) * 1960-07-12 1965-07-31 Wander Ag Dr A Verfahren zur Herstellung von Impfstoffen
US3987164A (en) * 1970-10-20 1976-10-19 Yuzuru Homma Method for prevention of pseudomonas aeruginosa infections
US4185090A (en) * 1972-02-02 1980-01-22 Abbott Laboratories Chemically modified endotoxin immunizing agent
NL7506560A (nl) * 1974-06-04 1975-12-08 Wellcome Found Werkwijze voor het bereiden van geconjugeerde pros- taglandinen.
JPS51106714A (OSRAM) * 1975-03-12 1976-09-21 Tokyo Daigaku
JPS5296729A (en) * 1976-02-05 1977-08-13 Shionogi & Co Ltd Mixed vaccin for cyanomycosis
FR2460139A1 (fr) * 1979-06-29 1981-01-23 Pasteur Institut Fraction antigenique glycopeptidique vaccinante a tres grande immunogenicite isolee de cultures de germes pathogenes, procedes d'isolement de cette fraction et vaccins contenant ladite fraction
JPS5639022A (en) * 1979-09-05 1981-04-14 Hayashibara Biochem Lab Inc Preparation of vaccine
US4285936A (en) * 1979-12-10 1981-08-25 The United States Of America As Represented By The Secretary Of The Army Method for producing a vaccine against bacterial infections caused by pseudomonas aeruginosa
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine

Also Published As

Publication number Publication date
EP0118831B1 (en) 1989-06-28
JPH0577657B2 (OSRAM) 1993-10-27
DE3478789D1 (en) 1989-08-03
EP0118831A2 (en) 1984-09-19
EP0118831A3 (en) 1986-12-10
EP0306607A1 (en) 1989-03-15
US4663160A (en) 1987-05-05
JPS59175440A (ja) 1984-10-04

Similar Documents

Publication Publication Date Title
ATE44238T1 (de) Vakzine fuer gramnegative bakterien und verfahren zur herstellung derselben.
SE7708845L (sv) Framstellning av d(-)-3-hydroxismorsyra
DE69826851D1 (de) Kopplung unmodifizierter proteinen an haloacyl- oder dihaloacyl-derivatisierten polysacchariden zur herstellung von protein-polysaccharide impfstoffen
DE69220746D1 (de) Verfahren zur Herstellung einer mehrfach ungesättigten Fettsäure des Omega 9 Typs
DE3486326D1 (de) Avirulenter Vibrio cholerae und Verfahren zu seiner Herstellung.
IE810618L (en) Pasteurella vaccines
DE69112716D1 (de) Verfahren zur biologischen Herstellung einer Hydroxyvitamin-D-Verbindung.
ATE161051T1 (de) Verfahren zur herstellung aktivierter sialinsäuren
ATE30713T1 (de) Isolierung von enzymatisch erzeugten carbonsaeuren.
EP0090660A3 (en) Neisseria gonorrhoeae vaccine
ATE80602T1 (de) Verfahren zur herstellung von hydroxybiphenylen.
DE68912236D1 (de) Verfahren zur Herstellung von hochgradig ungesättigten Fettsäuren.
ATE86666T1 (de) Verfahren zur herstellung von l-sorbose und vorrichtung zur kultivierung von mikroorganismen.
ATE127470T1 (de) Verfahren zur herstellung von phosphatidylcholinderivaten.
DE69531690D1 (de) Reinigungsverfahren für von bordetella produziertem nekrotoxin
KR840002855A (ko) Omt에스테르 유도체의 제조방법
ATE242332T1 (de) Verfahren zur herstellung einer l-aminosäure
DE3163814D1 (en) Homocitric acid oligoriboside derivatives, process for their manufacture and their use as preventives of dental caries
DE3877510D1 (de) Verfahren zur herstelllung von brenztraubensaeure.
ATE66151T1 (de) Verfahren zur herstellung von intravenoes geeigneten immunoglobulinen.
ATE121746T1 (de) Verfahren zur herstellung bissilylierter 3- iodmethylcephalosporinderivaten.
DE3583830D1 (de) Nortriptylinderivate, verfahren zu ihrer herstellung, deren konjugate mit antigenischen proteinen und enzymen, antikoerper davon und verwandte verfahren zur bestimmung.
SE8403929L (sv) Rekombinant-dna-molekyl, transformerade mikroorganismer och forfarande for framstellning av penicillin v-amidas
KR830007668A (ko) 6-아미노페니실란산 유도체의 제조방법
ATE21033T1 (de) Verfahren zur herstellung eines immunogens aus pasteurella multocida.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee